Table 1 (Contrave Er 01)
Contrave
Product Images NDC 50090-2945
7 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Contrave (NDC 50090-2945). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Naltrexone Hydrochloride Chemical Structure (Contrave Er 02)
Chemical structure diagram of the active ingredient in Contrave Extended-Release, showing detailed molecular bonds, rings, hydroxyl groups, and hydrochloride salt composition.*
Bupropion Hydrochloride Chemical Structure (Contrave Er 03)
Chemical structure diagram depicting the molecule of the active ingredient in Contrave Extended-Release by A-S Medication Solutions. The structure shows a chlorine-substituted benzene ring connected to a ketone and an amine group with associated hydrochloride salt.*
Figure 1 (Contrave Er 04)
A line graph depicting weight change from baseline (%) over 56 weeks, comparing Contrave Extended-Release 32/360 (black triangles) with placebo (open circles). The x-axis shows weeks, while the y-axis indicates percent weight change. Contrave shows a greater decrease in weight compared to placebo over time, with data segmented into completers and ITT-LOCF groups.*
Figure 1 (Contrave Er 05)
A line graph depicting weight change from baseline (%) over 56 weeks comparing placebo versus CONTRAVE 32/360. Weight change is shown on the Y-axis with time in weeks on the X-axis. Two lines display progressive weight loss, with CONTRAVE showing a greater decrease than placebo throughout the study period.*
Figure 1 (Contrave Er 06)
A line graph depicting weight change from baseline (%) over 56 weeks comparing placebo and CONTRAVE 32/360 treatments. The x-axis shows time in weeks, and the y-axis shows percent weight change. Two groups are shown: Placebo (open circles) and CONTRAVE 32/360 (filled triangles), with CONTRAVE showing a greater reduction in weight over time. Labels include 'Completers' and 'ITT-LOCF' to indicate analysis populations.*
Label Image (Lbl500902945)
Label for Contrave Extended-Release 8MG/90MG release tablets by A-S Medication Solutions. The label includes the product NDC 50090-2945-0, lot number 6721-0, storage instructions to keep at 77 degrees F, and a package size of 120 extended release tablets. It also displays a QR code and distributor information for A-S Medication Solutions in Libertyville, Illinois.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
